[SCHEDULE 13D/A] BIO-RAD LABORATORIES, INC. SEC Filing

Rhea-AI Filing Summary

Bio-Rad Laboratories (BIO) filed Schedule 13D/A (Amendment No. 7) updating beneficial ownership and control following family trust changes. Norman D. Schwartz reports beneficial ownership of 3,228,922 shares of Class A Common Stock, representing 14.6%. This includes 2,714,928 shares via trusts where he is sole trustee, 17,145 shares held by the Alles Institute for Medical Research with shared power, 443,434 shares held directly, and 53,415 options exercisable within sixty days of September 25, 2025.

The Alice N. Schwartz Revocable Trust holds 1,781,356 Class A shares, or 8.1%. Percentages are based on 21,992,307 Class A shares outstanding as of July 28, 2025, with Mr. Schwartz’s percentage calculated to include his 53,415 exercisable options. In Class B, Mr. Schwartz has beneficial ownership of 4,929,036 shares, or 97.2%, based on 5,070,184 Class B shares outstanding as of July 28, 2025. The filing states the purpose of the shareholders’ ownership has been control of the Company.

Insights

Governance & Ownership Analyst

Filing confirms concentrated control via Class B and trust succession.

Norman D. Schwartz reports 14.6% of Class A (3,228,922 shares) with a clear breakdown across trusts, direct holdings, and 53,415 options exercisable within sixty days of September 25, 2025. The Alice N. Schwartz Revocable Trust holds 8.1% of Class A (1,781,356 shares). Class A percentages use 21,992,307 outstanding as of July 28, 2025.

Control is anchored by Class B: Mr. Schwartz has beneficial ownership of 4,929,036 Class B shares, or 97.2%, based on 5,070,184 outstanding as of July 28, 2025. The document states the ownership purpose is control of the Company, and that he may be deemed a control person.

Key dependencies include trustee authority over specified trusts and option exercisability within the stated window. Subsequent filings may provide further updates to holdings as estate and trust transitions are finalized.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

Bio-Rad Laboratories, Inc.

(Name of Issuer)

Class A Common Stock

(Title of Class of Securities)

090572207

(CUSIP Number)

Norman D. Schwartz
1000 Alfred Nobel Drive,
Hercules, CA, 94547
5107247000

Courtney C. Enloe
Bio-Rad Laboratories, Inc., 1000 Alfred Nobel Drive
Hercules, CA, 94547
5107416005

John Duke
Hogan Lovells US LLP, 1735 Market Street, Suite 2300
Philadelphia, PA, 19103
2676754616

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/25/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 090572207

1

Name of reporting person

Norman D. Schwartz

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 3,211,777.00
8	Shared Voting Power 17,145.00
9	Sole Dispositive Power 3,211,777.00
10	Shared Dispositive Power 17,145.00

11

Aggregate amount beneficially owned by each reporting person

3,228,922.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.6 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(1) David Schwartz, Bio-Rad's former Chairman of the Board, and Alice N. Schwartz, a former Director Emeritus of Bio-Rad, each of whom was a reporting person in the Prior Filing (as defined in Item 1), are deceased. (7) (9) 2,714,928 of the reported securities are held by the following trusts, all of which Norman D. Schwartz is the sole trustee: the David and Alice N. Schwartz Charitable Remainder Unitrust (34,311 shares); the David Schwartz Exemption Trust (90 shares); the David Schwartz Exempt Marital Trust (240 shares); the David Schwartz Non-Exempt Marital Trust (898,931 shares); and the Alice N. Schwartz Revocable Trust (1,781,356 shares). Prior to her death, Alice N. Schwartz was the sole trustee of the aforementioned trusts. Upon her death, Norman D. Schwartz, Chief Executive Officer and Chairman of the Board of Directors of Bio-Rad, became the sole trustee of such trusts. Includes 443,434 shares held by Norman D. Schwartz directly and 53,415 shares with respect to which Norman D. Schwartz has the right to acquire beneficial ownership of, immediately or within sixty days of September 25, 2025, under Bio-Rad's stock option agreements. (8)(10) Held by the Alles Institute for Medical Research, a Delaware Charitable Nonstock Corporation, with respect to which Norman D. Schwartz shares voting and dispositive power consistent with the purposes of the Delaware Charitable Nonstock Corporation. (11) Percentage ownership calculation for "Percent of Class Represented by Amount in Row (11)" is calculated by using a denominator of (a) 21,992,307 shares of Class A Common Stock outstanding as of July 28, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on July 31, 2025, plus (b) 53,415 shares of Class A Common Stock issuable upon the exercise of stock options exercisable by Mr. Schwartz immediately or within sixty days of September 25, 2025.

SCHEDULE 13D

CUSIP No. 090572207

1

Name of reporting person

Alice N. Schwartz Revocable Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,781,356.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 1,781,356.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

1,781,356.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class A Common Stock
(b)	Name of Issuer: Bio-Rad Laboratories, Inc.
(c)	Address of Issuer's Principal Executive Offices: 1000 Alfred Nobel Drive, Hercules, CALIFORNIA , 94547.
Item 1 Comment: Reference is made to the statement on Schedule 13D filed with the Securities and Exchange Commission (the "Commission") on February 16, 1982 by David Schwartz, as last amended by Amendment No. 3 to the statement on Schedule 13D filed with the Commission on January 7, 1994 and revised on January 19, 1995 by David Schwartz, Amendment No. 4 to the statement on Schedule 13D filed with the Commission on December 14, 2011, Amendment No. 5 to the statement on Schedule 13D filed with the Commission on June 29, 2017 and Amendment No. 6 to the statement on Schedule 13D filed with the Commission on July 18, 2025 (the "Prior Filing"). Norman D. Schwartz and the Alice N. Schwartz Revocable Trust (sometimes collectively referred to as the "Shareholders") have agreed to file this statement jointly in an agreement entered into pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, and included as an exhibit to this statement, which agreement is hereby incorporated by reference. The Prior Filing is incorporated by reference and is hereby amended by this statement which is filed by the Shareholders, with respect to whom the following information relates. David Schwartz, Bio-Rad's former Chairman of the Board and a reporting person in the Prior Filing, passed away on April 1, 2012. Alice N. Schwartz, a former Director Emeritus of Bio-Rad and a reporting person in the Prior Filing, passed away on September 25, 2025. The Alice N. Schwartz Revocable Trust was added as a reporting person in Amendment No. 4 to the statement on Schedule 13D filed with the Commission on December 14, 2011. Norman D. Schwartz is being added as a reporting person in this Amendment No. 7 to the statement on Schedule 13D.
Item 2.	Identity and Background
(a)	Norman D. Schwartz
(b)	Norman D. Schwartz 1000 Alfred Nobel Drive Hercules, California 94547 (510) 724 - 7000
(c)	Norman D. Schwartz 1000 Alfred Nobel Drive Hercules, California 94547 (510) 724-7000 Chief Executive Officer and Chairman of the Board of Directors of Bio-Rad Laboratories, Inc. and the sole trustee of the Alice N. Schwartz Revocable Trust
(d)	During the last five years, neither Norman D. Schwartz nor the Alice N. Schwartz Revocable Trust has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	United States of America
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 to the Schedule 13D is hereby amended, in pertinent part, as follows: Not applicable.
Item 4.	Purpose of Transaction
	Item 4 to the Schedule 13D is hereby amended, in pertinent part, as follows: The purpose of the Shareholders' ownership of Bio-Rad shares has been control of the Company. Norman D. Schwartz, along with other members of his family, control the management of the Company and may be deemed to be a "parent" of the Company as that term is defined in the Rules and Regulations of the Commission.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 to the Schedule 13D is hereby amended, in pertinent part, as follows: (a)-(b). Norman D. Schwartz owns beneficially 3,228,922 shares of Class A Common Stock, representing 14.6% of the issued and outstanding Class A Common Stock. * 2,714,928 of these shares are held by the following trusts, all of which Norman D. Schwartz is the sole trustee: the David and Alice N. Schwartz Charitable Remainder Unitrust (34,311 shares); the David Schwartz Exemption Trust (90 shares); the David Schwartz Exempt Marital Trust (240 shares); the David Schwartz Non-Exempt Marital Trust (898,931 shares); and the Alice N. Schwartz Revocable Trust (1,781,356 shares). The shares held by the David Schwartz Exemption Trust, the David Schwartz Exempt Marital Trust, the David Schwartz Non-Exempt Marital Trust, and the Alice N. Schwartz Revocable Trust were previously held by the David and Alice Schwartz Revocable Trust, of which Alice N. Schwartz was the sole trustee after the death of her husband David Schwartz. On October 1, 2013, Alice N. Schwartz allocated these shares from the David and Alice Schwartz Revocable Trust to each of those trusts. On September 25, 2025, Norman D. Schwartz became the sole trustee of each of these trusts upon the death of his mother, Alice N. Schwartz. * 17,145 of these shares are held by the Alles Institute for Medical Research, a Delaware Charitable Nonstock Corporation, with respect to which Norman D. Schwartz shares voting and dispositive power consistent with the purposes of the Delaware Charitable Nonstock Corporation. * 443,434 of these shares are held by Norman D. Schwartz directly. * 53,415 of these shares are shares that Norman D. Schwartz has the right to acquire beneficial ownership of, immediately or within sixty days of September 25, 2025, under Bio-Rad's stock option agreements. The Alice N. Schwartz Revocable Trust holds 1,781,356 shares of Class A Common Stock, representing 8.1% of the issued and outstanding Class A Common Stock. All percentages reported herein with respect to Class A Common Stock are calculated based upon 21,992,307 shares of Class A Common Stock outstanding as of July 28, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on July 31, 2025. For Norman D. Schwartz, the beneficial ownership calculation is calculated by using a denominator of (a) 21,992,307 shares of Class A Common Stock plus (b) 53,415 shares of Class A Common Stock issuable upon the exercise of stock options exercisable by Mr. Schwartz immediately or within sixty days of September 25, 2025.
(c)	Not applicable
(d)	Not applicable
(e)	Due to the death of Mrs. Alice N. Schwartz, on September 25, 2025, Ms. Schwartz ceased to be a beneficial owner of more than 5% of the outstanding shares of Class A Common Stock of the Company.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Item 6 to the Schedule 13D is hereby amended, in pertinent part, as follows: Norman D. Schwartz has indirect beneficial ownership of 4,060,054 shares of Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of the Company held by Blue Raven Partners, L.P., a California limited partnership, over which he has shared voting and dispositive power, as the result of his position as a general partner of Blue Raven Partners, L.P. Mr. Schwartz is the beneficial owner of 494,510 shares of Class B Common Stock, over which he has sole voting power and which are held in the following trusts, all of which Mr. Schwartz is the sole trustee: the David Schwartz Non-Exempt Marital Trust (57,000 shares); and the Alice N. Schwartz Revocable Trust (437,510 shares). Mr. Schwartz holds 374,472 shares of Class B Common Stock but disclaims beneficial ownership with respect to 13,006 of such shares owned by his wife. As the result of the foregoing, Mr. Schwartz has beneficial ownership of an aggregate of 4,929,036 shares of Class B Common Stock, representing 97.2% of the issued and outstanding Class B Common Stock. The Alice N. Schwartz Revocable Trust is the direct and beneficial owner of 437,510 shares of Class B Common Stock with respect to which it has sole voting and dispositive power, representing 8.6% of the issued and outstanding Class B Common Stock. By virtue of his Class B Common Stock ownership, Mr. Schwartz, along with other members of his family, control the management of the Company and may be deemed to be a "control person" of the Company as that term is defined in the Rules and Regulations of the Commission. All percentages reported herein with respect to Class B Common Stock are calculated based upon 5,070,184 shares of Class B Common Stock outstanding as of July 28, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on July 31, 2025.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 - Agreement Among the Shareholders to File Joint Schedule 13D

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Norman D. Schwartz

Signature:	/s/ Norman D. Schwartz
Name/Title:	Norman D. Schwartz, Individually
Date:	10/28/2025

Alice N. Schwartz Revocable Trust

Signature:	/s/ Norman D. Schwartz
Name/Title:	Norman D. Schwartz, Trustee
Date:	10/28/2025

FAQ

What ownership did Norman D. Schwartz report in BIO’s Class A?

He reported beneficial ownership of 3,228,922 Class A shares, representing 14.6%.

How many Class A shares does the Alice N. Schwartz Revocable Trust hold?

The trust holds 1,781,356 Class A shares, representing 8.1%.

What share counts were used to calculate BIO Class A percentages?

Percentages use 21,992,307 Class A shares outstanding as of July 28, 2025; Mr. Schwartz’s figure also includes 53,415 exercisable options.

What is Norman D. Schwartz’s Class B ownership in BIO?

He has beneficial ownership of 4,929,036 Class B shares, or 97.2%, based on 5,070,184 outstanding as of July 28, 2025.

What is the stated purpose of the shareholders’ ownership?

The filing states the purpose has been control of the Company.

What components make up Mr. Schwartz’s Class A holdings?

They include 2,714,928 via trusts, 17,145 with shared power at the Alles Institute, 443,434 direct, and 53,415 options exercisable within sixty days of September 25, 2025.